Pricing and access
How much does Medicare spend on a drug? Part D and Part B data
Look up Medicare Part D spending by drug and Part B drug spending with free CMS data: what the numbers include, how rebates and ASP work, and how to rank drugs.
By the All In Biotech editorial team · Published November 18, 2026 · 6 min read
Medicare's spending on an individual drug is public. The Centers for Medicare & Medicaid Services (CMS) publishes yearly Part D and Part B Spending by Drug datasets showing total spending, claims, beneficiaries and spending per beneficiary for each drug. You can search those numbers on this site's Medicare drug spending tool, which currently covers calendar years 2020 through 2024.
The figures are gross spending, before manufacturer rebates. That one fact shapes how they should be read, and it is covered in detail below.
Part D and Part B: two different benefits
Medicare pays for drugs through two main parts of the program, and CMS publishes a separate dataset for each.
- Part D covers outpatient prescription drugs dispensed by pharmacies, including mail order. It is run by private plans that contract with Medicare. Most pills, inhalers and self-injected pens fall here.
- Part B covers drugs that a clinician gives in a doctor's office, clinic or hospital outpatient department, such as many infused cancer drugs and eye injections. Part B drugs are billed with HCPCS codes rather than by package.
The same active ingredient can appear in both datasets if it is sold in a self-administered form and a clinic-administered form. Drugs given during an inpatient hospital stay are generally paid as part of the hospital's bundled payment under Part A and are not broken out by drug in either dataset.
What the numbers show
In this site's copy of the CMS data (calendar 2024, as of November 2026), total gross drug spending in the datasets was:
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194.1B | $37.8B |
| 2021 | $213.5B | $40.1B |
| 2022 | $239.8B | $44.2B |
| 2023 | $275.8B | $50.8B |
| 2024 | $288.7B | $60.8B |
The Part D data has 3,625 brand and generic rows. The Part B data has 799 rows keyed by HCPCS code.
The largest Part D drugs by gross spending in 2024 were Eliquis ($20.77 billion, 4.42 million beneficiaries, about $4,695 per beneficiary), Ozempic ($12.97 billion), Jardiance ($11.44 billion), Mounjaro ($6.34 billion) and Xarelto ($6.23 billion). Trulicity, Trelegy Ellipta, Farxiga, the Humira pen and Revlimid complete the top ten.
In Part B, the largest drug in 2024 was Keytruda at $5.99 billion across 75,361 beneficiaries, followed by Darzalex Faspro ($2.53 billion), Prolia ($2.43 billion), Eylea ($2.37 billion) and Opdivo ($1.93 billion). Skin substitute products also rank high in Part B spending.
Reading each column
Each row in the tool shows:
- Spending: total gross spending for the year. For Part D this is the amount paid by plans, beneficiaries and other payers at the pharmacy. For Part B it is the Medicare-allowed amount, which includes the beneficiary's coinsurance.
- Change: the percentage change from the prior year. Large swings often reflect new uses, new competitors, generic entry or a shift between products, not only price.
- Beneficiaries: the number of Medicare enrollees with at least one claim. CMS suppresses small counts to protect privacy, so very small drugs may show "n/a".
- Per beneficiary: spending divided by beneficiaries. This is a rough average, not what any one patient pays.
- Per unit: the average spending per dosage unit, such as a tablet, milliliter or HCPCS billing unit. Units differ by product, so compare per-unit figures only between like products.
For Part B rows, the dataset also carries the average sales price (ASP) payment limit for the HCPCS code.
Sorting to answer different questions
The tool's "Rank by" menu turns the same data into different lists:
- Total spending shows where Medicare's drug dollars go. It favors drugs that are both widely used and expensive.
- Growth over prior year surfaces drugs whose spending is rising fastest. The tool skips drugs with less than $1 million in prior-year spending, so tiny bases do not dominate.
- Spending per beneficiary highlights high-cost drugs used by few people, often for rare diseases or cancer. Drugs with fewer than 11 beneficiaries are skipped.
- Beneficiaries shows the most widely used drugs, many of them inexpensive generics.
Filtering to Part B only is useful for clinic-administered biologics and biosimilars. The GLP-1 post shows how the same tool traces one drug class across five years.
Why gross spending is not net cost
Drug manufacturers pay rebates to Part D plans, and Medicare also receives other price concessions. These payments lower the real cost of many brand-name drugs, sometimes a great deal, but they are confidential and are not reported by drug in the public datasets. The Part D figures on this site, like CMS's own, are therefore gross amounts.
This has three practical consequences:
- Gross spending overstates what Medicare and plans ultimately pay for brands with large rebates, such as drugs in competitive classes.
- Comparisons between two brands can mislead if one carries larger rebates than the other.
- Gross spending for generics, which usually carry small or no rebates, is closer to net.
The data also does not show commercial insurance prices, list prices or what a patient pays at the pharmacy counter. Those are not public at the drug level.
How Part B drugs are paid
Most Part B drugs are paid at the average sales price plus 6 percent, under the payment formula in the Social Security Act. ASP is calculated from manufacturers' quarterly reports of their actual US sales prices, net of most discounts, so it already reflects some price concessions in a way Part D gross spending does not. CMS publishes the quarterly payment limits in its ASP pricing files. Special rules apply to some products, such as biosimilars and new drugs that do not yet have ASP data, and the rules change from time to time, so check CMS for current details.
The Medicare drug price negotiation program
The Inflation Reduction Act of 2022 gave Medicare authority to negotiate prices for some high-spending drugs that have been on the market for several years without generic or biosimilar competition. CMS runs the program in yearly cycles:
- Negotiated prices for the first 10 Part D drugs took effect on January 1, 2026. Several of the largest drugs in the 2024 data, including Eliquis, Jardiance and Xarelto, were in that first group.
- A second cycle of 15 Part D drugs has negotiated prices that take effect on January 1, 2027.
- On January 27, 2026, CMS announced 15 drugs for the third cycle, the first to include Part B drugs. Prices from that cycle take effect on January 1, 2028.
Because the spending data on this site runs through 2024, it does not yet reflect any negotiated price. Program details, the selected drug lists and the negotiated prices are on CMS's Medicare Drug Price Negotiation page. The program is still developing and its rules have been revised between cycles, so rely on CMS for the current status.
Where the data comes from
The datasets are published on data.cms.gov as Medicare Part D Spending by Drug and Medicare Part B Spending by Drug. CMS usually releases a new calendar year once claims are complete, which means the latest year is typically more than a year old. This site describes how it loads and matches the files in its methods notes.
Each drug page on this site also has a Medicare spending panel, so you can see the CMS figures next to the label and approval history. For example, the Ozempic page shows Part D spending alongside its approvals and safety reports. To find the drug first, start from the drug search or the free drug databases guide.
Frequently asked questions
- Where can I find how much Medicare spends on a specific drug?
- CMS publishes yearly Part D and Part B Spending by Drug datasets on data.cms.gov, and this site's pricing tool lets you search them by brand or generic name.
- Does Medicare Part D spending include rebates?
- No. The Part D figures are gross spending before manufacturer rebates and other price concessions, which CMS does not report by drug.
- What is the difference between Part D and Part B drug spending?
- Part D covers drugs dispensed by pharmacies, while Part B covers drugs given by a clinician in an office or hospital outpatient setting, which are usually paid based on average sales price.
- Which drug does Medicare Part D spend the most on?
- In CMS's 2024 data, Eliquis had the highest gross Part D spending at about $20.77 billion.
For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.